EverGlade BIO Leadership

Eric Jia-Sobota

Eric Jia-Sobota

Eric Jia-Sobota is the Founder of EverGlade BIO. With a professional journey spanning more than twenty years, Eric has cultivated a rich background in the Life Sciences Industry. Notably, Mr. Jia-Sobota possesses an extensive track record of aiding life sciences and nonprofit entities in securing research and development (R&D) funding. His collaboration with the Department of Health and Human Services (HHS), notably the Biomedical Advanced Research and Development Authority (BARDA), has been instrumental in facilitating responses to numerous pandemic scenarios.

Prior to establishing EverGlade BIO, Eric played a pivotal role in steering a National Consulting practice at an internationally recognized Accounting and Consulting firm, successfully expanding the team to include over 130 professionals within a remarkably short span. Additionally, he held key leadership positions across various other firms.

Steve Morris, PHD

Steve Morris, PhD

With over 25 years of experience in the fields of biotechnology and pharmaceutical development, Steve possesses a wealth of expertise. This includes an impressive track record of more than 13 years working within the US Government, notably as Chief of the Antivirals and Antitoxins branch within the CBRN Division of BARDA-ASPR, which falls under the purview of the HHS.

Dr. Morris has an intimate familiarity with the entire drug development lifecycle, spanning from initial discovery phases to preclinical and clinical development, culminating in the attainment of licensure or approval.

His proficiency extends to a comprehensive understanding of non-dilutive funding mechanisms within the United States Government (USG), encompassing skills in contract negotiation and the management of post-award contract administration and deliverables.

In his most recent role, he led a dedicated consulting team at one of the world’s largest accounting and consulting firms, strategically aiding clients in securing substantial funding, often in the range of hundreds of millions of dollars, through BARDA contracts and other Federal Awards.

Before venturing into consulting, Steve held a senior leadership position at a company specializing in vaccine development, further underlining his authoritative presence within the industry.

Scroll to Top